Loading company…
Step Pharma SAS is a French biotechnology company developing oncology therapies, led by dencatistat (STP938).
Its lead asset, dencatistat, is a first-in-class, orally bioavailable targeted therapy being studied for several cancers and other conditions, including lymphomas, solid tumors and autoimmune diseases. Founded in 2014 and based in Paris, France, the company is at the Series C stage. In October 2025 it raised EUR 38 million led by new investor V-Bio Ventures, with returning investors including Pontifax Venture Capital, Bpifrance, Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures and Inserm Transfert Initiative.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in